DARMSTADT, GERMANY: With the increase in the demand for the fertility treatment and growth hormone disorders treatment medicines, Merck has made a significant investment of €15 million over the period of 2014-2016 to expand its biotech plant in Tres Cantos, Madrid, Spain.
This results in a 50 percent rise in the production capacity its active substances for fertility treatment Gonal-f and growth hormone disorders treatment Saizen for the whole world.
This expansion improves 900 m2 of biotech production space and a 2-floor office building, leading to the overall constructed area to 8,000 m2. This plant meets the current Good Manufacturing Practices (cGMP) quality standards. The site employs 170 highly qualified experts, said the company.
“This expansion is a part of our pledge to deliver high-quality medicines at the right time to our patients,” said Simon Sturge, chief operating officer (COO) of the biopharma business of Merck.
© Worldofchemicals news